Product Images Pregabalin

This is a prescription medication called Pregabalin that comes in a package of 30 capsules. It is made by ScieGen Pharmaceuticals Inc. and distributed by MMER. It is a habit-forming drug, and the full prescribing information should be considered before use. The medication guide should also be dispensed with the medication. The capsules should be stored at 77 degrees Fahrenheit and kept out of the reach of children. The text includes GTIN, NDC, and serial numbers, but their use is not clear.*

This is a description of a medication containing Pregabalin 75 mg. It is advised to store the medication at 77 degrees F and keep it out of reach of children. The medication may be habit-forming and comes packaged and distributed by WMPWVW. The GTIN for the medication is 00355700805302, and the NDC is 55700-805-30. The medication is produced by ScieGen Pharmaceuticals, Inc., located in Hauppauge, NY 11788 and Holland, OH 43528 respectively. The text also mentions that each capsule contains Pregabalin, and there is a warning of the medication being habit-forming. Moreover, there is an instruction to refer to the medication guide when dispensing it. However, the last line of text is not readable.*

This text appears to be the packaging information for Pregabalin capsules, which are distributed by Zmz&ty Care Products. The capsules come in a package of 30 and each capsule contains 100 mg of Pregabalin. It is important to note that these capsules may be habit-forming and are only available with a prescription. The manufacturer is ScieGen Pharmaceuticals, Inc. and it is recommended to store the capsules at a temperature of 77 degrees F.*

This is a description of a medication containing Pregabalin 150mg, which may be habit-forming. It is packaged in a bottle of 60 capsules with GTIN: 00355700891602 and NDC: 55700-891-60. The medication should be stored at 77 degrees Fahrenheit and out of reach of children. The prescription was manufactured by ScieGen Pharmaceuticals, Inc., in Hauppauge, NY. There is a warning to dispense with a medication guide and a reference to the full prescribing information. However, there is no information on the lot number, expiration date, or any other relevant details.*

The text contains data on the percent of patients improved and percent improvement in pain from the baseline. The specific numbers provided are 8, 3, and some random characters that do not make any sense. It is not possible to identify any further useful information from this text.*

This data appears to represent a chart showing the percent improvement in pain from baseline for patients taking Pregabalin 160 mg for three days, with values of 100, 2, and 10. The chart includes partially readable numerical values for different time periods. A social media platform, likely Facebook, is also mentioned.*

This appears to be a table showing the effectiveness of three different treatments for pain relief: Fregabalin at 100mg three times per day, Pregataiin at 80mg three times per day, and a placebo. The data shows the number of patients who improved with each treatment, represented as 3, 8, and 888838838 respectively. There is also a chart showing the percent improvement in pain from each treatment compared to a baseline, ranging from 0.8% to 250%.*

The given text is a chart where the improvement in pain of patients taking Pregabalin at 300mg and 450mg daily doses has been plotted against the placebo. Therefore, no further useful description can be provided.*

This is a table that shows the estimated percentage of subjects without LTR (Likely Therapeutic Response) for two treatments, Progabain and Placebo, across different time points (in days). The percentage ranges from 0% to 100%, with increments of 10%. There is no further information available.*

This is a table presenting the percentage of improvement of subjects who took pregabalin compared to those who took a placebo from baseline to week 16 in a clinical trial. The percentages presented range from 100 to 280, with significant improvements observed in the pregabalin group.*